The following is a summary of the Eli Lilly and Company (LLY) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Eli Lilly reported Q1 revenue growth of 26% with new products contributing nearly $1.8 billion.

• Gross margin as a percent of revenue increased to 82.5% in Q1 2024, up from 78.4% in Q1 2023.

• The company delivered an EPS of $2.58 in Q1 2024, a 59% increase compared to Q1 2023.

• Full-year revenue outlook has been raised to between $42.4 - $43.6 billion.

Business Progress:

• Eli Lilly continues to invest in the launch and development of new medicines, with positive results for Phase 3 trials for tirzepatide.

• Expansion of the company's manufacturing capabilities is underway, including acquiring an injectable medicine facility and establishing a new manufacturing site in Germany.

• Discussions with the FDA are ongoing regarding the potential benefits of tirzepatide treatment for Non-Alcoholic Steatohepatitis (NASH), obesity, and other metabolic-related diseases.

• The company sees potential in donanemab as a treatment for early symptomatic Alzheimer's disease and is making progress in manufacturing scalability for orforglipron, expected to launch in 2026.

• Lilly is building a strong portfolio in radiopharmaceuticals, bringing in drugs like PNT2001, currently in Phase 1 trials for potential prostate cancer treatment.

More details: Eli Lilly and Co IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.